Both in Pharmaceuticals
Entrada Therapeutics vs Akebia Therapeutics
Over the past year TRDA returned −34.1% and AKBA returned −75.3%; their daily moves had a correlation of 0.43.
TRDA −34.1% AKBA −75.3%Growth of $1, one year, split-adjusted
| Metric | TRDA | AKBA |
|---|---|---|
| Price | $4.71 | $0.7292 |
| Market cap | $183.4M | $202.1M |
| Today | +6.80% | +10.43% |
| 1 month | −24.8% | −17.7% |
| 6 months | −63.0% | −46.4% |
| Year to date | −54.2% | −54.7% |
| 1 year | −35.6% | −77.0% |
| Revenue growth (YoY) | −53.9% | −21.4% |
| Gross margin | 100.0% | 78.8% |
| Net margin | −4762.0% | −18.1% |
| P/E (TTM) | — | — |
| Price / sales | 39.1× | 0.9× |
| Net cash | $223.0M | $106.0M |
| Dividend yield | — | — |
| Volatility (60d) | 76.0% | 92.1% |
| Short % of float | 13.0% | 8.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).